Identification of Critical Genes and Five Prognostic Biomarkers Associated with Colorectal Cancer

Zuoliang Huang
Qin Yang
Zezhi Huang

Background: Colorectal cancer (CRC) is a common malignant tumor with high incidence and mortality worldwide. The aim of this study was to evaluate the association between differentially expressed genes (DEGs), which may function as biomarkers for CRC prognosis and therapies, and the clinical outcome in patients with CRC.

Material/Methods: A total of 116 normal mucous tissue and 930 CRC tissue datasets were downloaded from the Gene Expression Omnibus database (GEO) and The Cancer Genome Atlas (TCGA). After screening DEGs based on limma package in R, Gene Ontology (GO) and KEGG enrichment analysis as well as the protein-protein interaction (PPI) networks were performed to predict the function of these DEGs. Meanwhile, Cox proportional hazards regression was used to build a prognostic model of these DEGs. Then, Kaplan-Meier risk analysis was used to test the model in TCGA datasets and validation datasets.

Results: In the present study, 300 DEGs with 100 upregulated genes and 200 downregulated genes were identified. The PPI networks including 162 DEGs and 256 nodes were constructed and 2 modules with high degree were selected. Moreover, 5 genes (MMP1, ACSL6, SMPD1, PPARGC1A, and HEPACAM2) were identified using the Cox proportional hazards stepwise regression. Kaplan-Meier risk curve in the TCGA and validation cohorts showed that high-risk group had significantly poor overall survival than the low-risk group.

Conclusions: Our study provided insights into the mechanisms of CRC formation and found 5 prognostic genes, which could potentially inform further studies and clinical therapies.

MeSH Keywords: Biological Markers • Colorectal Neoplasms • Databases, Genetic • Protein Interaction Maps • Survival Analysis

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/907224
Background

Colorectal cancer (CRC) is the second common tumor among females and the third among males, with an estimated 1,360,600 new cases and 693,900 related deaths in worldwide [1]. Despite advances in surgery, chemotherapy, as well as the development of molecular targeted therapy [2,3], the mortality of CRC is still increases [4]. This is due to, at least partly, the lack of diagnostic markers for detection of CRC and inefficient treatment of advanced colorectal cancer.

In recent years, significant progresses have been achieved in studying the molecular mechanisms of CRC formation. Mutations in the Wnt signaling pathway were reported as the most frequent cause of CRCS, such as adenomatous polyposis coli (APC). Mutations in APC result in accumulation of β-catenin which subsequently activates transcription of proto-oncogenes [5,6]. In addition, KRAS has been studied and shown to play important roles in the development of colorectal [7]. Low-frequency mutations in KRAS exon 2 were established as potential mechanisms of drug resistance from patients who respond to anti-epidermal growth factor receptor therapies [8]. Meanwhile, with the development of multiple molecular methods, more and more genes are being identified as being associated with this CRC. The genetic variations in interferon, specifically in interferon gamma, and interferon regulatory factors have been associated, with the increased risk of developing CRC and decreased survival after diagnosis [9]. Furthermore, upregulated expression of HspB5 was reported to have a positive association with TNM stages of CRC patients [10]. A gene microarray analysis suggested 3 significant signaling pathways (PI3K, p38, and ERK) were involved in HspB5-induced EMT in CRC cells, and which could prompt tumor cell proliferation and invasion [10].

Gene microarray and high-throughput sequence technology make it possible to analyze gene expression profiles during carcinogenesis and cancer progression. We can also identify new prognostic biomarkers based on genes expression profiles and clinical cases [11]. In the present study, differential expression genes (DEGs) were analyzed by estimating gene functions and protein-protein interaction (PPI) networks. We then identified 5 genes signatures with significant prognostic value by using the large clinical data from TCGA. The identified CRC related genes can aid in the discovery of new therapeutic targets for this disease and the prognostic 5 key genes model could be utilized to predict prognosis of patients with CRC.

Data source

The independent gene datasets (GSE71187 [12], GSE21815 [13], and GSE21510 [14]) with sample-sizes larger than 100 were extracted from the GEO database. RNA-seq datasets with the clinic information of CRC patients were downloaded from TCGA website. A total of 930 CRC tissues and 116 normal controls were analyzed to find DEGs. Validation datasets (GSE38832 [15] and GSE17536 [16], n >100), which include survival information, were downloaded from GEO.

Identification of DEGs

The original datasets were converted into recognizable format in R, the limma package [17] of R was used to normalize and identify DEGs from GEO datasets. The DEGs were selected out according to the criteria: |log (foldchange)|>1.5 and P<0.05. EdgeR package [18,19] of R was performed for the RNA-seq count datasets to find DEGs. The threshold of FDR <0.05 and |log2 (foldchange)| > 1.5 were used to screen out DEGs.

Functional enrichment analysis

The online software Database for Annotation Visualization and Integration Discovery (DAVID, Version 6.8, http://david.abcc.ncifcrf.gov/) [20] and KOBASS (version 3.0, http://kobas.cbi.pku.edu.cn/) [21,22] were used for Gene Ontology (GO) enrichment (P<0.01 was set as the threshold) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway functional enrichment (P<0.05 was set as the threshold), respectively.

PPI network construction and analysis

Protein-protein interactions of DEGs were identified by using the Search Tool for the Retrieval of Interacting Genes (STRING, version 10.5, https://string-db.org/) [23], a database which provides physical and functional association of protein. The DEG pairs interaction score >0.4 was selected to construct network. Then the PPIs between DEGs were visualized and analyzed using Cytoscape software (version 3.4) [24]. Furthermore, MCODE [25] was used to identify the modules in the PPI network with the parameters degree cutoff ≥2 and k-core ≥2. Finally, The GO and KEGG pathway enrichment of DEGs in the top 2 modules were performed. P<0.05 and counts >2 were set as the threshold.

Cox proportional hazards model construction and model validation

Expression datasets of fragments per kilobases per million (FPKM) values were download from TCGA. After replacing...
GO and KEGG pathway functional enrichment analyses were overlapped both in microarray and TCGA datasets (Figure 1). 300 DEGs were found to be significantly related to survival in the CRC samples; 3278 DEGs from TCGA RNA-seq datasets were found in the normal samples. Compared with the normal samples, 360 DEGs from microarray datasets and 3278 DEGs from TCGA RNA-seq datasets were significantly related to survival (P<0.05) were retained for further analyses.

Next, multivariable cox proportional hazards stepwise regression with backward selection was used to build a prognostic model. The prognostic risk score for predicting OS was calculated as: Risk score=\sum \beta_i \times \text{expGene (expGene: expression level of gene, } \beta_i \text{: the regression coefficient derived from the multivariable Cox regression model). Patients were divided into high-risk and low-risk groups by using the median risk score as the cutoff point. Then, proportional assumptions for Cox proportional hazard model were examined by Kaplan-Meier analysis. Receiver operating characteristic (ROC) was plotted and the area under curve (AUC) was calculated by using R package survival ROC [27]. Distribution of risk score, survival status, and gene expression levels of each patient were also analyzed and plotted using the R software.

Lastly, 2 independent datasets, GSE38832 [15] and GSE17536 [16], were used to validate the model of survival by Kaplan-Meier analysis.

**Results**

**DEG analysis**

Compared with the normal samples, 360 DEGs from microarray datasets and 3278 DEGs from TCGA RNA-seq datasets were found in the CRC samples; 300 DEGs were found to be overlapped both in microarray and TCGA datasets (Figure 1). GO and KEGG pathway functional enrichment analyses were performed to reveal the functions and mechanisms of DEGs (Figure 2).

**Construction and analysis of the PPI network**

A network containing a total of 162 DEGs and 256 nodes were identified (Figure 3A). Six modules were selected from the network by using MCODE and the top 2 were used for further analysis. Module 1 contained 2 upregulated DEGs (PPBP, CXCL11) and 6 downregulated DEGs (P2RY14, LPAR1, GNAI1, INSL5, NPY1R, CCL28, Figure 3B). Module 2 comprised 9 DEGs (9 upregulated genes), including TPX2, TRIP13, ECT2, ANLN, UBE2C, GINS1, DSCC1, RFC3, ATAD2 (Figure 3C). GO and KEGG pathway enrichment analysis revealed that differential expression genes in module 1 were significantly enriched in the pathway of gap junction (P<0.001), pathways in cancer (P<0.01), as well as the GO terms such as G-protein coupled receptor signaling pathway (P<0.001) and cell chemotaxis (P<0.05, Figure 4A). Moreover, differential expression genes in module 2 were significantly enriched for GO functions, including nucleolus (P<0.001), positive regulation of DNA-directed DNA polymerase activity (P<0.01) and ATP binding (P<0.05, Figure 4B).

**Identification of survival related DEGs**

A total of 24 significant survival-related DEGs (P<0.05) in the TCGA cohorts were identified. Multivariable Cox proportional hazards stepwise regression with backward selection was used to build a prognostic model. Five genes, MMP1, ACSL6, SMPD1, PPARGC1A, and HEPACAM2, which showed a significantly higher risk score, were selected (Table 1).

**Construction Cox regression model and data validation**

A linear model was calculated with the risk score=\sum (-0.1136 \times \text{MMP1}) + (-0.086 \times \text{ACSL6}) + (0.3534 \times \text{SMPD1}) + (-0.1809 \times \text{PPARGC1A}) + (-0.0647 \times \text{HEPACAM2}). Then, we calculated the risk score for each patient in the dataset. Patients were assigned into high-risk and low-risk groups by using the median risk score as the cutoff point. Kaplan-Meier risk curve revealed that patients in the high-risk group had a significantly shorter overall survival time than patients in the low-risk group (Figure 5A). ROC curve, which stood for the performance of the model, was plotted and the AUC of the risk score was up to 0.743 (Figure 5B). Furthermore, distribution of risk score, survival status, and gene expression level of each patient were also analyzed (Figure 5C).

For the verification of our survival model, 2 independent datasets, GSE38832 [15] and GSE17536 [16], were analyzed by Kaplan-Meier risk test (Figure 6). The 5 key genes model for prognosis were also considered effective on 2 independent datasets.
In recent decades, considerable efforts have been made to improve the clinical outcome of CRC patients [2,28]. However, CRC is still the leading cause of cancer-related deaths around the world [29]. Because of the heterogeneity of CRC, conventional prognostic systems of pathologic stages often show inefficient prediction for risk of CRC [30]. Many studies have been done to find suitable targets to predict outcomes for CRC patients [31,32]. However, reliable biomarkers and stable prognostic models for prediction prognosis in patients with CRC are still required.

In the present study, a total of 116 normal control tissue samples and 930 CRC tissue samples were retrieved from the GEO and TCGA. A total of 300 DEGs including 100 upregulated and 200 downregulated genes were identified. To demonstrate the molecular function of these abnormal DEGs, we performed GO and KEGG pathway analysis. DEGs were mainly enriched in the PI3K-AKT signaling pathway, PPAR signaling pathway, and WNT signaling pathway. In line with this, it would appear that an abnormal pathway would be a major cause of CRC [33–35]. In addition, DEGs were enriched in the GO terms of extracellular exosome, negative regulation of cell proliferation, and cell-cell adhesion. Strikingly, previous research has revealed the importance of these GO terms. Exosomes are now recognized as important mediators of cell-to-cell communication. Many studies have found exosomes to be important in tumor metastasis and tumor associated immunosuppressive [36,37]. Meanwhile, abnormal negative regulation of cell proliferation includes mutations of MYC. This leads to the unregulated expression of many genes, some of which are involved in cell proliferation and result in the formation of cancer [38]. Furthermore, abnormal cell adhesion has also been correlated with tumor invasion, metastasis, and poor prognosis of patients [39].

Gene expression profiles provide a global view of gene expression and enable identification of critical genes in cancer. However, the occurrence of false discovery results still exists [40]. To avoid false discovery and heterogeneity between different sequencing platforms, we combined 3 microarray datasets and RNA-seq datasets together. Finally, a gene

**Discussion**

In the present study, a total of 116 normal control tissue samples and 930 CRC tissue samples were retrieved from the GEO and TCGA. A total of 300 DEGs including 100 upregulated and 200 downregulated genes were identified. To demonstrate the molecular function of these abnormal DEGs, we performed GO and KEGG pathway analysis. DEGs were mainly enriched in the PI3K-AKT signaling pathway, PPAR signaling pathway, and WNT signaling pathway. In line with this, it would appear that an abnormal pathway would be a major cause of CRC [33–35]. In addition, DEGs were enriched in the GO terms of extracellular exosome, negative regulation of cell proliferation, and cell-cell adhesion. Strikingly, previous research has revealed the importance of these GO terms. Exosomes are now recognized as important mediators of cell-to-cell communication. Many studies have found exosomes to be important in tumor metastasis and tumor associated immunosuppressive [36,37]. Meanwhile, abnormal negative regulation of cell proliferation includes mutations of MYC. This leads to the unregulated expression of many genes, some of which are involved in cell proliferation and result in the formation of cancer [38]. Furthermore, abnormal cell adhesion has also been correlated with tumor invasion, metastasis, and poor prognosis of patients [39].

Gene expression profiles provide a global view of gene expression and enable identification of critical genes in cancer. However, the occurrence of false discovery results still exists [40]. To avoid false discovery and heterogeneity between different sequencing platforms, we combined 3 microarray datasets and RNA-seq datasets together. Finally, a gene

**Figure 2.** The results of the GO and pathway enrichment analyses of differentially expressed genes (DEGs). BP – biological process; CC – cellular component; MF – molecular function; KEGG – Kyoto Encyclopedia of Genes and Genomes; GO – Gene Ontology.

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).
A co-expression network containing 162 DEGs were constructed and 2 modules were extracted from the network. Several DEGs in the modules are considered important in the development of CRC. C-X-C motif chemokine ligand 11 (CXCL11) is considered as a chemokine for interleukin-activated T cells. A previous study showed that blocking CXCL11 had an influence on tumor growth and angiogenesis in C57 mice [41]. Meanwhile, microtubule nucleation factor (TPX2) is a spindle assembly factor required for normal assembly of mitotic spindles. TPX2 (20q11) promoted 20q amplicon-driven progression of colorectal adenoma to carcinoma [42]. Moreover, lysophosphatidic acid receptor 1 (LPAR1) is a receptor for lysophosphatidic acid (LPA). LPA1 could enhance DLD1 cell migration, proliferation, adhesion, and secretion of angiogenic factors, all of which are crucial for cancer metastasis [43]. Furthermore, ubiquitin-conjugating enzyme E2C (UBE2C) was reported to be associated with proliferative marker Ki-67, accumulation of cyclin A and a poor overall survival [44]. However, most DEGs were only roughly associated with the CRC, and failed to correlate with prognosis, which plays an important role in the survival rate of patients. To evaluate the association between DEGs and clinical outcome in patients with CRC, Cox univariate regression was carried out on 300 DEGs, and as a result, 24 genes were selected. Then these genes were analyzed by using Cox proportional hazards stepwise regression. Finally, we screened a 5 genes model comprised of MMP1, ACSL6, SMPD1, PPARGC1A, and HEPACAM2. Kaplan-Meier risk survival analysis showed that distinctive separation was observed in survival curves between patient groups with high-risk and low-risk scores. ROC analysis achieved an AUC of 0.743 which demonstrated relatively high sensitivity and specificity of the 5 genes signature model. To test the stability of our model, 2 irrelevant datasets, GSE38832 [15] and GSE17536 [16], were downloaded from GEO for verification of repeatability of our 5 prognostic genes. The 5 key genes were both effective on 2 independent datasets.

Our analysis is likely to provide biological and therapeutic information. Matrix metalloproteinase-1 (MMP-1) functions as an enzyme in the breakdown of extracellular matrix and plays a role in cancer progress [45]. It is the most studied gene of the 5, and is regarded as a biomarker for many cancers, including CRC and gastric cancer [45,46]. Acyl-CoA synthetase long-chain family member 6 (ACSL6) was found decreased in most forms of cancers, except CRC [48]. Data analysis revealed that ACSL6 emerged as a potential tumor suppressor gene in leukemia [48]. Sphingomyelin phosphodiesterase 1 (SMPD1) encodes lysosomal acid sphingomyelinase that converts sphingomyelin to ceramide. A previous study found that functional inhibition of acid sphingomyelinase...
### Table 1. Multivariate cox regression analysis of overall survival.

| Gene symbol | Coefficient | Hazard ratio (HR) | P value |
|-------------|-------------|------------------|---------|
| MMP1        | -0.114      | 0.893            | 0.001   |
| ACSL6       | -0.086      | 0.918            | 0.006   |
| SMPD1       | 0.353       | 1.424            | 0.001   |
| PPARGC1A    | -0.181      | 0.835            | 0.001   |
| HEPACAM2    | -0.065      | 0.937            | 0.017   |

Figure 4. The result of GO and pathway enrichment analyses of module 1 and module2. * BP – biological process; CC – cellular component; MF – molecular function; KEGG – Kyoto Encyclopedia of Genes and Genomes; GO – Gene Ontology.
Figure 5. Prognostic evaluation of the 5 genes signatures in colorectal cancer (CRC) patients. (A) Kaplan-Meier risk survival curve analysis for overall survival of CRC patients. (B) Receiver operating characteristic (ROC) curve analysis of 5 genes signatures. (C) The distribution of risk score, survival status, and gene expression level of patients.

Figure 6. Kaplan-Meier risk survival analyses of 2 independent datasets. (A) GSE38832 with 122 samples. (B) GSE39582 with 585 samples.
led to tumor cell death by overactivation of hypoxia stress-respons e pathways [49]. Peroxisome proliferator-activated receptor gamma coactivator 1-α (PPARGC1A or PGC1α) is a transcriptional coactivator able to upregulate mitochondrial biogenesis. PPARGC1A was found to protect against tumorigenesis by regulating the fate of enterocyte cell [50]. HEPCAM family member 2 (HEPACAM2) encodes a protein related to the immunoglobulin superfamily that plays a role in mitosis. HEPCAM was reported downregulated in breast cancer and induced senescence-like growth arrest by elevating the expression levels of senescence-associated proteins p21, p27, and p53 [51].

In summary, we have identified 300 DEGs by analyzing the datasets from GEO and TCGA. Further analysis revealed the function, mechanism, and protein-protein interaction networks of these DEGs. Moreover, 5 prognostic genes that were significantly associated with survival of CRC patients were identified in a large cohort by using Cox multivariate regression analysis. The identification of these DEGs as well as the prognostic genes for CRC will be beneficial for future research and clinical adjuvant therapies. However, larger sample size studies and future basic research are needed to confirm the significance of these DEGs and 5 prognostic genes.

Conclusions

Our study identified critical genes and 5 prognostic biomarkers associated with colorectal cancer, which will be beneficial for future research and clinical therapies.

Acknowledgments

The result shown here were based on the analysis of datasets from TCGA (http://cancergenome.nih.gov/) and GEO (http://www.ncbi.nlm.nih.gov/geo/).

Conflict of interest

None.

References:

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. Cancer J Clin, 2005; 55: 74–108
2. Sadanandam A, Lyssiotis CA, Homiccko K et al: A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med, 2013; 19: 619–25
3. Colon Cancer Laparoscopic or Open Resection Study Group, Buunen M, Veldkamp R, Hop WC et al: Survival after laparoscopic surgery versus open surgery for colon cancer: Long-term outcome of a randomised clinical trial. Lancet Oncol, 2009; 10: 44–52
4. Arnold M, Sierra MS, Laevensanne M et al: Global patterns and trends in colorectal cancer incidence and mortality. Gut, 2017; 66(4): 683–91
5. Sameer AS: Colorectal cancer: Molecular mutations and polymorphisms. Front Oncol, 2013; 3: 114
6. Krausova M, Korinek V: Wnt signaling in adult intestinal stem cells and cancer. Cell Signal, 2014; 26: 570–79
7. Li Y, Gao X, Qiu Z, Xu H et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol, 2008; 26: 374–79
8. Tougeron D, Lecomte T, Pages J et al: Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol, 2013; 24: 1267–73
9. Slattery ML, Lundgreen A, Bondurant KL, Wolff RK: Interferon-signaling pathway: Associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis, 2011; 32: 1660–67
10. Li Q, Wang Y, Lai Y et al: HspB5 correlates with poor prognosis in colorectal cancer and prompts epithelial-mesenchymal transition through ERK signaling. PLoS One, 2017; 12: e0182588
11. Shukla S, Evans JR, Malik R et al: Development of a RNA-Seq based prognostic signature in lung adenocarcinoma. J Natl Cancer Inst, 2016; 109(1): pii: djw200
12. An N, Shi X, Zhang Y et al: Discovery of a novel immune gene signature with profound prognostic value in colorectal cancer: A model of co- operativity disorientation created in the process from development to cancer. PLoS One, 2015; 10: e0137171
13. Iwaya T, Yokobori T, Nishida N et al: Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis, 2012; 33: 2391–97
14. Tsukamoto S, Ishikawa T, Iida S et al: Clinical significance of osteoprotegerin expression in human colorectal cancer. Clin Cancer Res, 2011; 17: 2444–50
15. Tripathi MK, Deane NG, Zhu J et al: Nuclear factor of activated T-cell activity is associated with metastatic capacity in colon cancer. Cancer Res, 2014; 74: 6947–57
16. Freeman TJ, Smith JJ, Chen X et al: Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin. Gastroenterology, 2012; 142: 562–71.e2
17. Ritchie ME, Phipson B, Wu D et al: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 2015; 43: e47
18. McCarthy DJ, Chen Y, Smyth GK: Differential expression analysis of multi-factor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res, 2012; 40: 4288–97
19. Robinson MD, McCarthy DJ, Smyth GK: edger: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 2010; 26: 139–40
20. Huang DW, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 2009; 4: 44
21. Wu J, Mao X, Cai T et al: KOBAS server: A web-based platform for automatic annotation and pathway identification. Nucleic Acids Res, 2006; 34: W720–24
22. Xie C, Mao X, Huang J et al: KOBAS 2.0: A web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res, 2011; 39: W316–22
23. Szklarczyk D, Morris JK, Cook H et al: The STRING database in 2017: Quality-controlled protein–protein association networks, made broadly accessible. Nucleic acids Res, 2017; 45: D362–68
24. Smoot ME, Ono K, Ruscheinski J et al: Biocyc database: An anatomy of large-scale molecular networks. Nucleic Acids Res, 2009; 37: W625–30
25. Bader GD, Hogue CW: An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics, 2003; 4: 2
26. Aalen OO: A linear regression model for the analysis of life times. Stat Med, 1989; 8: 907–25
27. Heagerty PJ, Zheng Y: Survival model predictive accuracy and ROC curves. Biometrics, 2005; 61: 92–105
28. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med, 2005; 352: 476–87

© Med Sci Monit, 2018; 24: 4625-4633

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
29. Torre LA, Siegel RL, Ward EM, Jemal A: Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev, 2016; 25: 16–27
30. Linnekamp JF, Wang X, Medema JP, Vermeulen L: Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. Cancer Res, 2015; 75: 245–49
31. Liu D-R, Guan Q-L, Gao M-T et al: miR-1260b is a potential prognostic biomarker in colorectal cancer. Med Sci Monit, 2016; 22: 3352–61
32. Dong S-j, Cai X-j, Li S-j: The clinical significance of MiR-429 as a predictive biomarker in colorectal cancer patients receiving 5-fluorouracil treatment. Med Sci Monit, 2016; 22: 3352–61
33. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature, 2000; 405: 421–24
34. Johnson SM, Gulhati P, Rampy BA et al: Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg, 2010; 210: 767–76
35. Bientz M, Clevers H: Linking colorectal cancer to Wnt signaling. Cell, 2000; 103: 311–20
36. Ji H, Greening DW, Barnes TW et al: Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics, 2013; 13: 1672–86
37. Taylor DD, Gercel-Taylor C: Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol, 2011; 33(S): 441–54
38. Pomerantz MM, Ahmadiyeh N, Jia L et al: The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet, 2009; 41: 882–84
39. Mulder J-W, Sewnath M, Offerhaus G et al: Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet, 1994; 344: 1470–72
40. Glickman ME, Rao SR, Schultz MR: False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. J Clin Epidemiol, 2014; 67: 850–57
41. Rupertus K, Sinistra J, Scheuer C et al: Interaction of the chemokines i-TAC (CCL11) and SDF-1 (CCL12) in the regulation of tumor angiogenesis of colorectal cancer. Clin Exp Metastasis, 2014; 31: 447–59
42. Sillars-Hardebol A4, Carvalho B, Tijssen M et al: TPF2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut, 2012; 61: 1568–75
43. Shida D, Kitayama J, Yamaguchi H et al: Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res, 2003; 63: 1706–11
44. Bavi P, Uddin S, Ahmed M et al: Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma. Am J Pathol, 2011; 178: 2109–20
45. Sunami E, Tsuno N, Osada T et al: MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist, 2000; 5: 108–14
46. Fujimoto D, Hirono Y, Goi T et al: Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer. Anticancer Res, 2008; 28: 847–54
47. Lopes-Marques M, Cunha I et al: Diversity and history of the long-chain acyl-CoA synthetase (Acsl) gene family in vertebrates. BMC Evol Biol, 2013; 13: 271
48. Chen W-C, Wang C-Y, Hung Y-H et al: Systematic analysis of gene expression alterations and clinical outcomes for long-chain acyl-coenzyme A synthetase family in cancer. PLoS One, 2016; 11: e0155660
49. Klutzny S, Lesche R, Keck M et al: Functional inhibition of acid sphingomyelinase by Fluphenazine triggers hypoxia-specific tumor cell death. Cell Death Dis, 2017; 8: e2709
50. D’Errico I, Salvatore L, Murzilli S et al: Peroxisome proliferator-activated receptor-y coactivator 1-alpha (PGC1a) is a metabolic regulator of intestinal epithelial cell fate. Proc Natl Acad Sci, 2011; 108: 6603–8
51. Moh MC, Zhang T, Lee LH, Shen S: Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells. Carcinogenesis, 2008; 29: 2298–305

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]